Peptides DB
Research-centric peptide and protocol reference hub
Study 11 of 11TB-500 Ac-LKKTETQ literaturebiorxiv-preprint · Observational2026

Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities

Many users report improvements when using BPC-157 and TB-500 for injuries, but the lack of medical supervision and high side effect rates are concerning.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the tb-500 ac-lkktetq corpus
1
Preclinical
9
Observational · this one
0
Open-label
1
Randomised
0
Reviews

Summary and findings

This study analyzed the use of unapproved peptides BPC-157 and TB-500 for musculoskeletal injuries among users in online communities. The median dose for BPC-157 was reported as 366 mcg per injection, with 79.3% of users stating an improvement in their condition. Side effects were reported by 27.2% of users, with fatigue, anxiety, anhedonia, and insomnia being the most common.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
79.3% reported improvement among those stating an outcome.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>Objective: </h4> To describe how people use the unapproved peptides BPC-157 and TB-500 for tendon, ligament and muscle injury and what side effects they report. <h4>Methods:</h4> Using a large language model validated against physician review, we analyzed 92,254 posts and comments from 28,652 users in Reddit's peptide communities from 2021 to 2026. We compared side effects with those reported by users of four other peptides in the same communities. <h4>Results:</h4> In all, 5,588 users described using BPC-157 and/or TB-500 for a specific musculoskeletal injury, most often a chronic tendon problem of the shoulder, knee or elbow. Only 3.8% of users described physician involvement, and 90.9% of those naming a source bought from research-chemical vendors. The median BPC-157 dose (366 mcg per injection) was about 2.7 times the human-equivalent dose of the 10 mcg/kg rat regimen, and among new users it rose from 300 mcg in 2024 to 500 mcg in 2025. Of those stating an outcome, 79.3% reported improvement, and 36.6% of all users were also in physical therapy. Overall, 27.2% described at least one side effect, most often fatigue, anxiety, anhedonia and insomnia. Anhedonia was more common than among users of the four other peptides (10.2% versus 1.3% of those with side effects). <h4>Conclusion:</h4> Use of these unapproved peptides for musculoskeletal injury is largely unsupervised, relying on grey-market products at self-selected, rising doses without established safety or efficacy.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the TB-500 Ac-LKKTETQ corpus

BLongevity Peptides and Functional Reserve: An Evidence Audit of Approved Peptides Against the Capacities That Keep Older Adults Independentbiorxiv-preprint · 2023 · Not reported in abstract.reviewDThymosin beta4 induces adult epicardial progenitor mobilization and neovascularization.Nature · 2007—BRising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notesbiorxiv-preprint · 2023 · n=1536 · 79% of 354 BPC-157 users with a directional response reported symptomatic improvement.HumanBCo-creating a community health research agenda with a youth advisory group in rural Cambodia: process, involvement, and outcomesbiorxiv-preprint · 2026 · Diabetes ranked 9.1/10 in concern.HumanBEffect of transitioning virally suppressed children and adolescents with HIV to dolutegravir-based antiretroviral therapy: emulated target trials in a large cohort in South Africabiorxiv-preprint · 2026 · RD -5·2 [95% CI -5·8 to -4·6]HumanBDeep sequencing reveals subpopulation dynamics associated with treatment failure in a rare non-tuberculous mycobacterial infectionbiorxiv-preprint · 2026 · 444 unique SNPs identified in 12 longitudinal isolates.Human